Germero 1G Injection contains Meropenem 1000 mg, a broad-spectrum carbapenem antibiotic effective against a wide range of Gram-positive and Gram-negative bacteria, including multidrug-resistant strains. It is indicated for the treatment of severe bacterial infections such as complicated intra-abdominal infections, bacterial meningitis, complicated skin and soft tissue infections, and complicated urinary tract infections including pyelonephritis. Meropenem exerts its bactericidal action by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins, leading to cell lysis and death. Germero 1G Injection is administered intravenously, allowing rapid systemic distribution and high tissue penetration, essential for managing severe infections. Dosage and duration of therapy should be tailored based on the severity of infection, renal function, and patient response. Caution is advised in patients with a history of hypersensitivity to beta-lactams and in those with impaired renal function, where dose adjustment is necessary. Common adverse effects include gastrointestinal disturbances, rash, and potential for Clostridium difficile-associated diarrhea. Germero 1G Injection should be used under strict medical supervision, ensuring appropriate microbiological diagnosis and susceptibility testing to optimize therapeutic outcomes and minimize resistance development.